Thematic review series: Recent advances in the treatment of lysosomal storage diseases: Gene therapy for the neurological manifestations in lysosomal storage disorders

Journal of Lipid Research

Volumn 55, Issue 9, 2014, Pages 1827-1838

  Cheng, Seng H ^a  

^a SANOFI   (France)

Author keywords

Adeno associated virus; Hematopoietic stem cells; Inherited metabolic diseases; Lentivirus; Neurodegenerative diseases

Indexed keywords

ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; LYSOSOMAL STORAGE DISEASES;

ANIMALS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LYSOSOMAL STORAGE DISEASES; TRANSDUCTION, GENETIC;

EID: 84906853788     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R047175     Document Type: Review

References (166)

1. Neufeld, E. F. 1991. Lysosomal storage diseases. Annu. Rev. Biochem. 60: 257-280.
2. Ballabio, A., and V. Gieselmann . 2009 . Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta. 1793: 684-696.
3. Platt, F. M., B. Boland, and A. C. van der Spoel. 2012. Lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J. Cell Biol. 199: 723-734.
4. Meikle, P. J., J. J. Hopwood, A. E. Clague, and W. F. Carey. 1999. Prevalence of lysosomal storage disorders. JAMA. 281: 249-254. (Pubitemid 29058114)
5. Fuller, M., P. J. Meikle, and J. J. Hopwood. 2006. Epidemiology of lysosomal storage diseases: an overview. In Fabry Disease: Perspectives from 5 Years of FOS. A. Mehta, M. Beck, and G. Sunder-Plassmann, editors. Oxford PharmaGenesis, Oxford. 9-20.
6. Wraith, J. E. 2004. Clinical aspects and diagnosis. In Lysosomal Disorders of the Brain. F. M. Platt and S. U. Walkley, editors. Oxford University Press, Oxford. 50-77.
7. Sardiello, M., M. Palmieri, A. di Ronza, D. L. Medina, M. Valenza, V. A. Gennarino, C. di Malta, F. Donaudy, V. Embrione, R. S. Banfi, et al. 2009. A gene network regulating lysosomal biogenesis and function. Science. 325: 473-477.
8. Palmieri, M., S. Impey, H. Kang, A. di Ronza, C. Pelz, M. Sardiello, and A. Ballabio. 2011. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 20: 3852-3866.
9. Settembre, C., C. di Malta, V. A. Polito, M. Garcia Arencibia, F. Ventrini, S. Erdin, S. U. Erdin, T. Huynh, D. Medina, P. Colella, et al. 2011. TFEB links autophagy to lysosomal biogenesis. Science. 332: 1429-1433.
10. Vitner, E. B., F. M. Platt, and A. H. Futerman . 2010 . Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem. 285: 20423-20427.
11. Walkley, S. U. 2004. Pathogenic cascades and brain dysfunction. In Lysosomal Disorders of the Brain. F. M. Platt and S. U. Walkley, editors. Oxford University Press, Oxford. 290-324.
12. Fratantoni, J. C., C. W. Hall, and E. F. Neufeld. 1968. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science. 162: 570-572.
13. Brady, R. O. 2006. Enzyme replacement for lysosomal diseases. Annu. Rev. Med. 57: 283-296. (Pubitemid 43261992)
14. Desnick, R. J., E. H. Schuchman, K. H. Astrin, and S. H. Cheng. 2013. Therapies for lysosomal storage diseases. In Emery and Rimoin's Principles and Practice of Medical Genetics. 6th edition. D. Rimoin, R. Pyeritz, and B. Korf, editors. Academic Press, Oxford. 1-30.
15. Wenk, J., A. Hille, and K. von Figura . 1991 . Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem. Int. 23: 723-731.
16. Pohlmann, R., M. W. Boeker, and K. von Figura. 1995. The two mannose 6-phosphate receptors transport distinct complements of lysosomal proteins. J. Biol. Chem. 270: 27311-27318.
17. Achord, D. T., F. E. Brot, C. E. Bell, and W. S. Sly. 1978. Human β-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell. 15: 269-278. (Pubitemid 9027530)
18. Barton, N. W., R. O. Brady, J. M. Dambrosia, A. M. di Bisceglie, S. H. Doppelt, S. C. Hill, H. J. Mankin, G. J. Murray, R. I. Parker, C. E. Argoff, et al. 1991. Replacement therapy for inherited enzyme deficiency-macrophage- targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324: 1464-1470.
19. Wilcox, W. R., M. Banikazemi, N. Guffon, S. Waldek, P. Lee, G. E. Linthorst, R. J. Desnick, and D. P. Germain. 2004. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75: 65-74.
20. Wraith, J. E., L. A. Clarke, M. Beck, E. H. Kolodny, G. M. Pastores, J. Muenzer, D. M. Rapoport, K. I. Berger, S. J. Swiedler, E. D. Kakkis, et al. 2004. Enzyme replacement therapy for mucopolysac-haridosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J. Pediatr. 144: 581-588. (Pubitemid 38594757)
21. Sly, W. S. 2004. Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice. Mo. Med. 101: 100-104.
22. Nicolino, M., B. Byrne, J. E. Wraith, N. Leslie, H. Mandel, D. R. Freyer, G. L. Arnold, E. K. Pivnick, C. J. Ottinger, P. H. Robinson, et al. 2009. Clinical outcomes after long-term treatment with aglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 11: 210-219.
23. Zhu, Y., J-L. Jiang, N. K. Gumlaw, J. Zhang, S. D. Bercury, R. J. Ziegler, K. Lee, M. Kudo, W. M. Canfield, T. Edmunds, et al. 2009. Glycoengineered acid α-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17: 954-963.
24. Cheng, S. H., and A. E. Smith. 2003. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther. 10: 1275-1281. (Pubitemid 36987117)
25. Sands, M. S., and B. L. Davidson. 2006. Gene therapy for lysosomal storage diseases. Mol. Ther. 13: 839-849.
26. Sloniowski, S. P., J. C. Fox, and S. J. Gray. 2013. Perspectives in using gene therapy for lysosomal storage diseases. Drugs Future. 38: 635-643.
27. Yew, N. S., and S. H. Cheng. 2013. Gene therapy for lysosomal storage disorders. Pediatr. Endocrinol. Rev. 11: 99-109.
28. Shihabuddin, L. S., and S. H. Cheng. 2011. Neural stem cell transplantation as a therapeutic approach for treating lysosomal storage diseases. Neurotherapeutics. 8: 659-667.
29. van Gelder, C. M., A. A. M. Vollebregt, I. Plug, A. T. van der Ploeg, and A. J. J. Reuser. 2012. Treatment options for lysosomal storage disorders: developing insights. Expert Opin. Pharmacother. 13: 2281-2299.
30. Boelens, J. J., V. K. Prasad, J. Tolar, R. F. Wynn, and C. Peters. 2010. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr. Clin. North Am. 57: 123-145.
31. Cox, T., R. Lachmann, C. Hollack, J. Aerts, S. van Weely, M. Hrebicek, F. Platt, T. Butters, R. Dwek, C. Moyses, et al. 2000. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 355: 1481-1485. (Pubitemid 30237353)
32. Patterson, M. C., D. Vecchio, H. Prady, L. Abel, and J. E. Wraith. 2007. Miglustat for treatment of Niemann-Pick C disease: a randomized controlled study. Lancet Neurol. 6: 765-772. (Pubitemid 47238662)
33. Passini, M. A., E. B. Lee, G. G. Heuer, and J. H. Wolfe. 2002. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J. Neurosci. 22: 6437-6446. (Pubitemid 35386400)
34. Dodge, J. C., J. Clarke, A. Song, J. Bu, W. Yang, T. V. Taksir, D. Griffiths, M. A. Zhao, E. H. Schuchman, S. H. Cheng, et al. 2005. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann Pick type A disease. Proc. Natl. Acad. Sci. USA. 102: 17822-17827. (Pubitemid 41803581)
35. Bosch, A., E. Perret, N. Desmaris, and J. M. Heard. 2000. Longterm and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther. 1: 63-70.
36. Liu, G., I. Martins, J. A. Wemmie, J. A. Chiorini, and B. L. Davidson. 2005. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci. 25: 9321-9327. (Pubitemid 41464744)
37. Cachón-González, M. B., S. Z. Wang, A. Lynch, R. Ziegler, S. H. Cheng, and T. M. Cox. 2006. Effective gene therapy in an authentic model of Tay-Sachs related diseases. Proc. Natl. Acad. Sci. USA. 103: 10373-10378.
38. Passini, M. A., J. Bu, J. A. Fidler, R. J. Ziegler, J. W. Foley, J. C. Dodge, W. W. Yang, J. Clarke, T. V. Taksir, D. A. Griffiths, et al. 2007. Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc. Natl. Acad. Sci. USA. 104: 9505-9510. (Pubitemid 47185809)
39. Luca, T., M. I. Givori, L. Perani, F. Galbiati, A. Follenzi, L. Naldini, and E. R. Bongarzone. 2005. Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. Mol. Ther. 12: 669-679. (Pubitemid 41350148)
40. Ellinwood, N. M., C. H. Vite, and M. E. Haskins. 2004. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J. Gene Med. 6: 481-506. (Pubitemid 40228065)
41. Casal, M., and M. Haskins. 2006. Large animal models and gene therapy. Eur. J. Hum. Genet. 14: 266-272.
42. Mittermeyer, G., C. W. Christine, K. H. Rosenbluth, S. L. Baker, P. Starr, P. Larson, P. L. Kaplan, J. Forsayeth, M. J. Aminoff, and K. S. Bankiewicz. 2012. Long-term evaluation of a Phase 1 study of AADC gene therapy for Parkinson's disease. Hum. Gene Ther. 23: 377-381.
43. Gritti, A. 2011. Gene therapy for lysosomal storage disorders. Expert Opin. Biol. Ther. 11: 1153-1167.
44. Byrne, B. J., D. J. Falk, N. Clement, and C. S. Mah. 2012. Gene therapy approaches for lysosomal storage disease: next generation treatment. Hum. Gene Ther. 23: 808-815.
45. Tomanin, R., A. Zanetti, E. Zaccariotto, F. D'Avanzo, C. M. Bellettato, and M. Scarpa. 2012. Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases. Acta Paediatr. 101: 692-701.
46. Simonato, M., J. Bennett, N. M. Boulis, M. G. Castro, D. J. Fink, W. F. Goins, S. J. Gray, P. R. Lowenstein, L. H. Vanderberghe, T. J. Wilson, et al. 2013. Progress in gene therapy for neurological disorders. Nat. Rev. Neurol. 9: 277-291.
47. Passini, M. A., J. C. Dodge, J. Bu, W. Yang, Q. Zhao, D. Sondhi, H. R. Hackett, S. M. Kaminsky, Q. Mao, L. S. Shihabuddin, et al. 2006. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classic late infantile neuronal ceroid lipofuscinosis. J. Neurosci. 26: 1334-1342. (Pubitemid 43237004)
48. Bu, J., K. M. Ashe, J. Bringas, J. Marshall, J. C. Dodge, M. A. Cabrera-Salazar, J. Forsayeth, E. H. Schuchman, K. S. Bankiewicz, S. H. Cheng, et al. 2012. Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol. Ther. 20: 1893-1901.
49. Gray, S. J., S. Nagabhushan Kalburgi, T. J. McCown, and R. J. Samulski. 2013. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in nonhuman primates. Gene Ther. 20: 450-459.
50. Cabrera-Salazar, M. A., E. M. Roskelley, J. Bu, B. L. Hodges, N. Yew, J. C. Dodge, L. S. Shihabuddin, I. Sohar, D. E. Sleat, R. K. Scheule, et al. 2007. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol. Ther. 15: 1782-1788. (Pubitemid 47434184)
51. Rahim, A. A., A. M. Wong, K. Hoefer, S. M. Buckley, C. N. Mattar, S. H. Cheng, J. K. Chan, J. D. Cooper, and S. N. Waddington. 2011. Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J. 25: 3505-3518.
52. David, A. L., and S. N. Waddington. 2012. Candidate diseases for prenatal gene therapy. Methods Mol. Biol. 891: 9-39.
53. Peters, C., M. Balthazor, E. G. Shapiro, R. J. King, C. Kollman, J. D. Hegland, J. Henslee-Downey, M. E. Trigg, M. J. Cowan, J. Sanders, et al. 1996. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 87: 4894-4902. (Pubitemid 26162394)
54. Aldenhoven, M., J. J. Boelens, and T. J. de Koning. 2008. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol. Blood Marrow Transplant. 14: 485-498. (Pubitemid 351494741)
55. Atchison, R. W., B. C. Casto, and W. M. Hammon. 1965. Adenovirus-associated defective virus particles. Science. 149: 754-756.
56. McCarty, D. M., S. M. Young, and R. J. Samulski. 2004. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38: 819-845. (Pubitemid 40013747)
57. Duan, D., P. Sharma, J. Yang, Y. Yue, L. Dudus, Y. Zhang, K. J. Fisher, and J. F. Engelhardt. 1998. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 72: 8568-8577. (Pubitemid 28471794)
58. Donsante, A., C. Vogler, N. Muzycka, J. M. Crawford, J. Barker, T. Flotte, M. Campbell-Thompson, T. Daly, and M. S. Sands. 2001. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 8: 1343-1346. (Pubitemid 32834303)
59. Donsante, A., D. G. Miller, Y. Li, C. Vogler, E. M. Brunt, D. W. Russell, and M. S. Sands. 2007. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 317: 477. (Pubitemid 47196106)
60. Gao, G. P., M. R. Alvira, L. Wang, R. Calcedo, J. Johnston, and J. M. Wilson. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA. 99: 11854-11859. (Pubitemid 34994488)
61. Gao, G., L. H. Vandenberghe, and J. M. Wilson. 2005. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5: 285-297. (Pubitemid 40895013)
62. Maheshri, N., J. T. Koerber, B. K. Kaspar, and D. V. Schaffer. 2006. Directed evolution of adeno-associated yields enhanced gene delivery vectors. Nat. Biotechnol. 24: 198-204. (Pubitemid 43221704)
63. Wu, Z., A. Asokan, and R. J. Samulski. 2006. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14: 316-327. (Pubitemid 44184972)
64. Bartel, M. A., J. R. Weinstein, and D. V. Schaffer. 2012. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther. 19: 694-700.
65. Cearley, C. N., and J. H. Wolfe. 2006. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9 and Rh10 in the mouse brain. Mol. Ther. 13: 528-537. (Pubitemid 43257620)
66. Swain, G. P., M. Prociuk, J. H. Bagel, P. O'Donnell, K. Berger, K. Drobatz, B. L. Gurda, M. E. Haskin, M. S. Sands, and C. H. Vite. 2014. Adeno-associated virus serotypes 9 and rh10 mediate strong neuronal transduction of the dog brain. Gene Ther. 21: 28-36.
67. Foust, K. D., E. Nurre, C. L. Montgomery, A. Hernandez, C. M. Chan, and B. K. Kaspar. 2009. Intravascular AAV9 preferentially targets neonatal neurons and astrocytes. Nat. Biotechnol. 27: 59-65.
68. Zhang, H., B. Yang, X. Mu, S. S. Ahmed, Q. Su, R. He, H. Wang, C. Mueller, M. Sena-Esteves, R. Brown, et al. 2011. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19: 1440-1448.
69. Calcedo, R., L. H. Vandenberghe, G. Gao, J. Lin, and J. M. Wilson. 2009. Worldwide epidemiology of neutralizing antibodies to adeno- associated viruses. J. Infect. Dis. 199: 381-390.
70. Boutin, S., V. Monteilhet, P. Veron, C. Leborgne, O. Benveniste, M. F. Montus, and C. Masurier. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21: 704-712.
71. McCarty, D. M., P. E. Monahan, and R. J. Samulski. 2001. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8: 1248-1254. (Pubitemid 32780813)
72. Gray, S. J., S. B. Foti, J. W. Schwartz, L. Bachaboina, B. Taylor-Blake, J. Coleman, M. D. Ehlers, M. J. Zylka, T. J. McCowan, and R. J. Samulski. 2011. Optimizing promoters for recombinant adeno- associated virus-mediated gene expression in the periphera; and central nervous system using self-complementary vectors. Hum. Gene Ther. 22: 1143-1153.
73. Husain, T., M. A. Passini, M. K. Parente, N. W. Fraser, and J. H. Wolfe. 2009. Long-term AAV gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters. Gene Ther. 16: 927-932.
74. Xia, H., Q. Mao, and B. L. Davidson. 2001. The HIV Tat protein transduction domain improves the biodistribution of β- glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol. 19: 640-644. (Pubitemid 32625434)
75. Blanz, J., S. Stroobants, R. Lullmann-Rauch, W. Morelle, M. Ludemann, R. D'Hooge, H. Reuterwall, J. C. Michalski, J. Fogh, C. Andersson, et al. 2008. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in α-mannosidosis mice. Hum. Mol. Genet. 17: 3437-3445.
76. Matzner, U., R. Lullman-Rauch, S. Stroobants, C. Andersson, C. Weigelt, C. Eistrup, J. Fogh, R. D'Hooge, and V. Gieselmann. 2009. Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol. Ther. 17: 600-606.
77. Dierenfeld, A. D., M. F. McEntee, C. A. Vogler, C. H. Vite, A. H. Chen, M. Passage, S. Le, S. Shah, J. K. Jens, E. M. Snella, et al. 2010. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci. Transl. Med. 2: 60ra89.
78. Kamata, Y., A. Tanabe, A. Kanaji, M. Kosuga, Y. Fukuhara, X. K. Li, S. Suzuki, M. Yamada, N. Azuma, and T. Oyuyama. 2003. Longterm normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharisosis VII. Gene Ther. 10: 406-414. (Pubitemid 36372448)
79. Chung, S., X. Ma, Y. Liu, D. Lee, M. Tittiger, and K. P. Ponder. 2007. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol. Genet. Metab. 90: 181-192. (Pubitemid 46108606)
80. Ruzo, A., M. Garcia, A. Ribera, P. Villacampa, V. Haurigot, S. Marco, E. Avuso, X. M. Anguela, C. Roca, J. Agudo, et al. 2012. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol. Ther. 20: 254-266.
81. Nathwani, A. C., E. G. Tuddenham, S. Rangaraian, C. Rosales, J. McIntosh, D. C. Linch, P. Chowdary, A. J. Pie, C. Harrington, J. O'Beirne, et al . 2011. Adeno-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365: 2357-2365.
82. Gaudet, D., J. Methot, S. Dery, D. Brisson, C. Essiembre, G. Tremblay, K. Tremblay, J. de Wal, J. Twisk, N. van den Bulk, et al. 2013. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 20: 361-369.
83. Boado, R. J., J. Z. Lu, E. K. Hui, R. K. Sumbria, and W. M. Pardridge. 2013. Pharmokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol. Bioeng. 110: 1456-1465.
84. Samaranch, L., E. A. Salegio, W. San Sebastian, A. P. Kells, K. D. Foust, J. R. Bringas, C. Lamarre, J. Forsayeth, B. K. Kaspar, and K. S. Bankiewicz. 2012. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23: 382-389.
85. Fu, H., J. Dirosario, S. Killedar, K. Zaraspe, and D. M. McCarty. 2011. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol. Ther. 19: 1025-1033.
86. Chen, Y. H., K. Claflin, J. C. Geoghegan, and B. L. Davidson. 2012. Sialic acid deposition impairs the utility of AAV9, but not peptidemodified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol. Ther. 20: 1393-1399.
87. Bevan, A. K., S. Duque, K. D. Foust, P. R. Morales, L. Braun, L. Schmelzer, C. M. Chan, M. McCrate, L. G. Chicoine, B. D. Coley, et al. 2011. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19: 1971-1980.
88. Work, L. M., H. Buning, E. Hunt, S. A. Nicklin, L. Denby, N. Britton, K. Leike, M. Odenthal, U. Drebber, M. Hallek, et al. 2006. Vascular bed-targeted in vivo gene delivery using tropismmodified adeno-associated viruses. Mol. Ther. 13: 683-693.
89. Büning, H., L. Perabo, O. Coutelle, S. Quadt-Humme, and M. Hallek. 2008. Recent developments in adeno-associated virus technology. J. Gene Med. 10: 717-733.
90. Chen, Y. H., M. Chang, and B. L. Davidson. 2009. Unique molecular signatures of disease brain endothelia provide a novel site for CNS-directed enzyme therapy. Nat. Med. 15: 1215-1218.
91. Grieger, J. C., and R. J. Samulski. 2012. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol. 507: 229-254.
92. Manno, C. S., G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, et al. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12: 342-347. [Erratum. 2006. Nat. Med. 12: 592.] (Pubitemid 43355084)
93. Hurlbut, G. D., R. J. Ziegler, J. B. Nietupski, J. W. Foley, L. A. Woodworth, E. Meyers, S. D. Bercury, D. W. Souza, M. P. Bree, M. J. Lukason, et al. 2010. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther. 18: 1983-1994.
94. Gray, S. J., V. Matagne, L. Bachabonia, S. Yadav, S. R. Ojeda, and R. J. Samulski. 2011. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19: 1058-1069.
95. Treleaven, C. M., T. J. Tamsett, J. Bu, J. A. Fidler, S. P. Sardi, G. D. Hurlbut, L. A. Woodworth, S. H. Cheng, M. A. Passini, L. S. Shihabuddin, et al. 2012. Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies. Mol. Ther. 20: 1713-1723.
96. Cearley, C. N., and J. H. Wolfe. 2007. A single injection of an adeno- associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 27: 9928-9940. (Pubitemid 47404014)
97. Kakkis, E., M. McEntee, C. Vogler, S. Le, B. Levy, P. Belichenko, W. Mobley, P. Dickson, S. Hanson, and M. Passage. 2004. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol. Genet. Metab. 83: 163-174. (Pubitemid 39328075)
98. Chang, M., J. D. Cooper, D. E. Sleat, S. H. Cheng, J. C. Dodge, M. A. Passini, P. Lobel, and B. L. Davidson. 2008. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 16: 649-656. (Pubitemid 351426165)
99. Dodge, J. C., J. Clarke, C. M. Trevleaven, T. V. Taksir, D. A. Griffiths, W. Yang, J. A. Fidler, M. A. Passini, K. P. Karey, E. H. Schuchman, et al. 2009. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp. Neurol. 215: 349-357.
100. Calias, P., M. Papisov, J. Pan, N. Savioli, V. Belov, Y. Huang, J. Lotterhand, M. Alessandrini, N. Liu, A. J. Fischman, et al. 2012. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS ONE. 7: e30341.
101. Auclair, D., J. Finnie, S. U. Walkley, J. White, T. Nielsen, M. Fuller, A. Cheng, C. A. O'Neill, and J. J. Hopwood. 2012. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr. Res. 71: 39-45.
102. Haurigot, V., S. Marcó, A. Ribera, M. Garcia, A. Ruzo, P. Villacampa, E. Ayuso, S. Añor, A. Andaluz, M. Pineda, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J. Clin. Invest. Epub ahead of print. July 1, 2013; doi:10.1172/JCI66778.
103. Elliger, S. S., C. A. Elliger, C. P. Aguilar, N. R. Raju, and G. L. Watson. 1999. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther. 6: 1175-1178. (Pubitemid 29295225)
104. Passini, M. A., D. J. Watson, C. H. Vite, D. J. Landsburg, A. L. Feigenbaum, and J. H. Wolfe. 2003. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of β-glucuronidase-deficient mice. J. Virol. 77: 7034-7040. (Pubitemid 36666896)
105. Deleted in proof.
106. Watson, G., J. Bastacky, P. Belichenko, M. Buddhikot, S. Jungles, M. Vellard, W. C. Mobley, and E. Kakkis. 2006. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther. 13: 917-925.
107. Broekman, M. L., R. C. Baek, L. A. Comer, J. L. Fernandez, T. N. Seyfried, and M. Sena-Esteves. 2007. Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. Mol. Ther. 15: 30-37. (Pubitemid 46043646)
108. Deleted in proof.
109. Chauhan, A. N., and P. D. Lewis. 1979. A quantitative study of cell proliferation in ependymal and choroid plexus in the postnatal rat brain. Neuropathol. Appl. Neurobiol. 5: 303-309. (Pubitemid 10000195)
110. Hennig, A. K., B. Levy, J. M. Ogilvie, C. A. Vogler, N. Galvin, S. Bassnett, and M. S. Sands. 2003. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J. Neurosci. 23: 3302-3307. (Pubitemid 36531971)
111. Cressant, A., N. Desmaris, L. Verot, T. Brejot, R. Froissart, N. T. Vanier, I. Maire, and J. M. Heard. 2004. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci. 24: 10229-10239. (Pubitemid 39492050)
112. Broekman, M. L., L. A. Tierney, C. Benn, P. Chawla, J. H. Cha, and M. Sena-Esteves. 2009. Mechanisms of distribution of mouse beta-galactosidase in the adult GM1-gangliosidosis brain. Gene Ther. 16: 303-308.
113. Salegio, E. A., L. Samaranch, A. P. Kells, G. Mittermeyer, W. San Sebastian, S. Zhou, J. Beyer, J. Forsayeth, and K. S. Bankiewicz. 2013. Axonal transport of adeno-associated viral vectors is sero-type- dependent. Gene Ther. 20: 348-352.
114. Salegio, E. A., A. P. Kells, R. M. Richardson, P. Hadaczek, J. Forsayeth, J. Bringas, S. P. Sardi, M. A. Passini, L. S. Shihabuddin, S. H. Cheng, et al. 2010. Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum. Gene Ther. 21: 1093-1103.
115. Piguet, F., D. Sondhi, M. Piraud, F. Fouguet, N. R. Hackett, O. Ahouansou, M. T. Vanier, I. Bieche, P. Aubourg, R. G. Crystal, et al. 2012. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum. Gene Ther. 23: 903-914.
116. Sevin, C., A. Benraiss, D. Van Dam, D. Bonnin, G. Nagels, L. Verot, I. Laurendeau, M. Vidaud, V. Gieselman, M. Vanier, et al. 2006. Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Hum. Mol. Genet. 15: 53-64. (Pubitemid 43020104)
117. Sondhi, D., N. R. Hackett, D. A. Peterson, J. Stratton, M. Baad, K. M. Travis, J. M. Wilson, and R. G. Crystal. 2007. Enhanced survival of the LINCL mouse dollowing CLN2 gene transfer using the rh.1- rhesus macaque-derived adeno-associated virus vector. Mol. Ther. 15: 481-491.
118. Desmaris, N., L. Verot, J. P. Puech, C. Caillaud, M. T. Vanier, and J. M. Heard. 2004. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. 56: 68-76. (Pubitemid 38857361)
119. Ellinwood, N. M., J. Ausseil, N. Desmaris, S. Bigou, S. Liu, J. K. Jens, E. M. Snella, E. E. Mohammed, C. B. Thompson, S. Raoul, et al. 2011. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol. Ther. 19: 251-259.
120. Fu, H., L. Kang, J. S. Jennings, S. S. Moy, A. Perez, J. Dirosario, D. M. McCarty, and J. Muenzer. 2007. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther. 14: 1065-1077. (Pubitemid 47029490)
121. Frisella, W. A., L. H. O'Connor, C. A. Vogler, M. Roberts, S. Walkley, B. Levy, T. M. Daly, and M. S. Sands. 2001. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol. Ther. 3: 351-358. (Pubitemid 32514651)
122. Lin, D., C. R. Fantz, B. Levy, M. A. Rafi, C. Vogler, D. A. Wenger, and M. S. Sands. 2005. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoidcell leukodystrophy more efficiently than AAV2. Mol. Ther. 12: 422-430. (Pubitemid 41150127)
123. Griffey, M. A., D. Wozniak, M. Wong, E. Bible, K. Johnson, S. M. Rothman, A. E. Wentz, J. D. Cooper, and M. S. Sands. 2006. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol. Ther. 13: 538-547. (Pubitemid 43257621)
124. Vite, C. H., M. A. Passini, M. E. Haskins, and J. H. Wolfe. 2003. Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther. 10: 1874-1881. (Pubitemid 37258634)
125. Ciron, C., N. Desmaris, M. A. Colle, S. Raoul, B. Joussemet, L. Verot, J. Ausseil, R. Froissart, F. Roux, Y. Cherel, et al. 2006. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol. 60: 204-213. (Pubitemid 44182395)
126. Bradbury, A. M., J. N. Cochran, V. J. McCurdy, A. K. Johnson, B. L. Brunson, H. Gray-Edwards, S. G. Leroy, M. Hwang, A. N. Randle, L. S. Jackson, et al. 2013. Therapeutic response in feline Sandhoff disease despite immunity to intracranial gene therapy. Mol. Ther. 21: 1306-1315.
127. Vite, C. H., J. C. McGowan, S. N. Niogi, M. A. Passini, K. J. Drobatz, M. E. Haskins, and J. H. Wolfe. 2005. Effective gene therapy for an inherited CNS disease in a large animal model. Ann. Neurol. 57: 355-364. (Pubitemid 40343957)
128. Hadaczek, P., J. Forsayeth, H. Mirek, K. Munson, J. Bringas, P. Pivirotto, J. L. McBride, B. L. Davidson, and K. S. Bankiewicz. 2009. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum. Gene Ther. 20: 225-237.
129. Leone, P., C. G. Janson, L. Bilaniuk, Z. Wang, F. Sorgi, L. Huang, R. Matalon, R. Kaul, Z. Zeng, A. Freese, et al. 2000. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann. Neurol. 48: 27-38. [Erratum. 2000. Ann. Neurol. 48: 398.] (Pubitemid 30432428)
130. McPhee, S. W., C. G. Janson, C. Li, R. J. Samulski, A. S. Camp, J. Francis, D. Shera, L. Lioutermann, M. Feely, A. Freese, et al. 2006. Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med. 8: 577-588. (Pubitemid 43827251)
131. Crystal, R. G., D. Sondhi, N. R. Hackett, S. M. Kaminsky, S. Worgall, P. Stieg, M. Souweidane, S. Hosain, L. Heier, D. Ballon, et al. 2004. Clinical protocol. Administration of a replicationdeficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. 15: 1131-1154. (Pubitemid 39552294)
132. Worgall, S., D. Sondhi, N. R. Hackett, B. Kosofsky, M. V. Kekatpure, N.
133. Leone, P., D. Shera, S. W. McPhee, J. S. Francis, E. H. Kolodny, L. T. Bilaniuk, D. J. Wang, M. Assadi, O. Goldfarb, H. W. Goldman, et al. 2012. Long-term follow-up after gene therapy for Canavan disease. Sci. Transl. Med. 4: 165ra163.
134. Krivit, W., P. Aubourg, E. Shapiro, and C. Peters. 1999. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr. Opin. Hematol. 6: 377-382. (Pubitemid 29503144)
135. Souillet, G., N. Guffon, I. Maire, M. Pujol, P. Taylor, F. Sevin, N. Bleyzac, C. Mulier, A. Durin, K. Kebaili, et al. 2003. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated hematopoietic stem cell sources. Bone Marrow Transplant. 31: 1105-1117. (Pubitemid 36857368)
136. Escolar, M. L., M. D. Poe, J. M. Provenzale, K. C. Richards, J. Allison, S. Wood, D. A. Wenger, D. Pietryga, D. Wall, M. Champagne, et al. 2005. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N. Engl. J. Med. 352: 2069-2081. (Pubitemid 40664308)
137. Priller, J., A. Flugel, T. Wehner, M. Boentert, C. A. Haas, M. Prinz, F. Fernandez-Klett, K. Prass, I. Bechmann, B. A. de Boer, et al. 2001. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fl uorescent protein uncovers microglial engraftment. Nat. Med. 7: 1356-1361. (Pubitemid 34007942)
138. Asheuer, M., F. Pfumio, S. Benhamida, A. Dubart-Kupperschmitt, F. Fouquet, Y. Imai, P. Aubourg, and N. Cartier. 2004. Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc. Natl. Acad. Sci. USA. 101: 3557-3562. (Pubitemid 38338234)
139. Ajami, B., J. L. Bennett, C. Krieger, W. Tetzlaff, and F. M. Rossi. 2007. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 10: 1538-1543. (Pubitemid 350175883)
140. Rovelli, A. M. 2008. The controversial and changing role of haemotopoietic cell transplantation for lysosomal storage disorders: an update. Bone Marrow Transplant. 41: S87-S89. (Pubitemid 351864715)
141. Biffi, A., A. Capotondo, S. Fasano, U. del Carro, S. Marchesini, H. Azuma, M. C. Malaguti, S. Amadio, R. Brambilla, M. Grompe, et al. 2006. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J. Clin. Invest. 116: 3070-3082. (Pubitemid 44684492)
142. Visigalli, I., S. Delai, L. S. Politi, C. Di Domenico, F. Cerri, E. Mrak, R. D'Isa, D. Ungaro, M. Stok, F. Sanvito, et al. 2010. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood. 116: 5130-5139.
143. Naldini, L., U. Biomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272: 263-267. (Pubitemid 26119138)
144. Kay, M. A., J. C. Glorioso, and L. Naldini. 2001. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7: 33-40. (Pubitemid 32095639)
145. Azzouz, M., and N. Mazarakis. 2004. Non-primate E1AV-based lentiviral vectors as gene delivery system for motor neuron diseases. Curr. Gene Ther. 4: 277-286. (Pubitemid 39162389)
146. Miyoshi, H., U. Blomer, M. Takahashi, F. H. Gage, and I. M. Verma. 1998. Development of a self-inactivating lentivirus vector. J. Virol. 72: 8150-8157.
147. Vigna, E., and L. Naldini. 2000. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med. 2: 308-316.
148. Su, K., D. Wang, J. Ye, Y. C. Kim, and S. A. Chow. 2009. Site-specific integration of retroviral DNA in human cells using fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc-finger protein E2C. Methods. 47: 269-276.
149. Sakuma, T., M. A. Barry, and Y. Ikeda. 2012. Lentiviral vectors: basic to translational. Biochem. J. 443: 603-618.
150. Matzner, U., F. Schestag, D. Hartman, R. Lullmann-Rauch, R. D'Hooge, R. P. De Deyn, and V. Gieselmann. 2001. Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells. Hum. Gene Ther. 12: 1021-1033. (Pubitemid 32692419)
151. Biffi, A., M. De Palma, A. Quattrini, U. Del Carro, S. Amadio, I. Visigalli, M. Sessa, S. Fasano, R. Brambilla, S. Marchesini, et al. 2004. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest. 113: 1118-1129. (Pubitemid 38544097)
152. Sano, R., A. Tessitore, A. Ingrassia, and A. d'Azzo. 2005. Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood. 106: 2259-2268. (Pubitemid 41510794)
153. Wang, D., W. Zhang, T. A. Kalfa, G. Grabowski, S. Davies, P. Malik, and D. Pan. 2009. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc. Natl. Acad. Sci. USA. 106: 19958-19963.
154. Gentner, B., I. Visigalli, H. Hiramatsu, E. Lechman, S. Ungari, A. Giustacchini, G. Schira, M. Amendola, A. Quattrini, S. Martino, et al. 2010. Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci. Transl. Med. 2: 58ra84.
155. Sergijenko, A., A. Langford-Smith, A. Y. Liao, C. E. Pickford, J. McDermott, G. Nowinski, K. J. Langford-Smith, C. L. Merry, S. A. Jones, J. E. Wraith, et al. 2013. Myeloid/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol. Ther. 21: 1938-1949.
156. Cavazzana-Calvo, M., S. Hacein-Bey, G. de Saint Basile, E. Yvon, P. Nusbaum, F. Selz, C. Hue, S. Certain, J. L. Casanova, P. Bousso, et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288: 669-672. (Pubitemid 30241569)
157. Ferrua, F., I. Brigida, and A. Auiti. 2010. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr. Opin. Allergy Clin. Immunol. 10: 551-556.
158. Roselli, E. A., R. Mezzadra, M. C. Frittoli, G. Maruggi, E. Biral, F. Mavilio, F. Mastropietro, A. Amato, G. Tonon, C. Refaldi, et al. 2010. Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol. Med. 2: 315-328.
159. Aiuti, A., L. Biasco, S. Scaramuzza, F. Ferrua, M. P. Cicalese, C. Baricordi, F. Dionisio, A. Calabria, S. Giannelli, M. C. Castiello, et al. 2013. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 341: 1233151.
160. Biffi, A., E. Montini, L. Lorioli, M. Cesani, F. Fumagalli, T. Plati, C. Baldoli, S. Martino, A. Calabria, S. Canale, et al. 2013. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 341: 1233158.
161. Philippidis, A. 2013. Gene therapy briefs. Hum. Gene Ther. 24: 965-967.
162. Wilson, J. M. 2013. Bulls, bubbles, and biotech. Hum. Gene Ther. 24: 715-716.
163. Hawkins-Salsbury, J. A., A. S. Reddy, and M. S. Sands. 2011. Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts? Hum. Mol. Genet. 20: R54-R60.
164. Sidransky, E., and G. Lopez. 2012. The link between the GBA gene and parkinsonism. Lancet Neurol. 11: 986-998.
165. Manzoni, C., and P. A. Lewis. 2013. Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB J. 27: 3424-3429.
166. Sardi, S. P., J. Clarke, C. Viel, M. Chan, T. J. Tamsett, C. M. Treleaven, J. Bu, L. Sweet, M. A. Passini, J. C. Dodge, et al. 2013. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. USA . 110: 3537-3542.